A new treatment approach for myelofibrosis, tagraxofusp, demonstrates a manageable safety profile and modest clinical activity when used as a single therapy, according to findings from a phase 1/2 clinical trial. The research, focused on patients with varying stages of the disease, offers a potential new avenue for treatment, particularly for those who are not candidates for stem cell transplantation or have become resistant to existing therapies.
Myelofibrosis is a rare type of blood cancer that disrupts the body’s normal production of blood cells. Symptoms can include fatigue, anemia and an enlarged spleen. Current treatment options are limited, making the exploration of new therapies like tagraxofusp crucial for improving patient outcomes. This CD123-targeted therapy has been under investigation for its potential to address the underlying causes of the disease and alleviate symptoms.
Tagraxofusp: Safety and Dosage in Clinical Trials
The phase 1/2 trial aimed to determine the optimal dosage of tagraxofusp and assess its safety and effectiveness in two groups of patients: those with newly diagnosed myelofibrosis and those whose disease had become resistant or unresponsive to Janus kinase (JAK) inhibitors. Researchers found no dose-limiting toxicities associated with the treatment. The recommended dose for the phase 2 portion of the trial was established at 12 μg/kg per day for three consecutive days per cycle, as determined by the study published in Blood Neoplasia.
While generally well-tolerated, the treatment did present some side effects. The most frequently reported grade 3 or higher adverse events included anemia, thrombocytopenia (low platelet count), and shortness of breath. Some patients experienced capillary leak syndrome during the initial treatment cycle, but this condition generally resolved. Pharmacists can play a key role in monitoring for these potential complications, particularly capillary leak syndrome and cytopenias.
Clinical Activity and Patient Response
Among 18 patients with splenomegaly (enlarged spleen) at the beginning of the trial, two who had previously been treated with and become resistant to JAK inhibitors experienced a spleen volume reduction of 35% or more. In patients who had relapsed or were refractory to prior treatment, 40% demonstrated a Total Symptom Score (TSS) improvement of 50% or greater, with a median overall survival of 19.3 months. For patients who were newly diagnosed with myelofibrosis, 40% also achieved a TSS improvement of 50% or more, and had a median overall survival of 26.6 months.
The trial also indicated that tagraxofusp did not demonstrate cumulative myelotoxicity, meaning that the treatment did not progressively damage the bone marrow over time. This finding is particularly encouraging, as myelosuppression is a common and serious side effect of many cancer treatments. Researchers noted that the therapy was associated with symptom score improvements.
Future Directions and Combination Therapies
The researchers emphasize that these findings support further investigation into the employ of tagraxofusp in combination with other treatments. The modest clinical activity observed with monotherapy suggests that combining tagraxofusp with other agents may enhance its effectiveness. Early data suggests that exploring these combination therapies is a promising next step in the development of more effective treatments for myelofibrosis.
The ongoing research into tagraxofusp represents a significant step forward in the fight against myelofibrosis. While further studies are needed to fully understand its potential, the current findings offer hope for improved treatment options and better outcomes for patients battling this challenging disease.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have you or a loved one been affected by myelofibrosis? Share your experiences in the comments below. Please also share this article with anyone who might find it helpful.
